FDA approves Moderna's RSV vaccine for seniors, the company's second-ever product

📆 31-5-2024 17:27:00
📰 NBCNewYork

⏱ Reading Time:
27 sec. here
2 min. at publisher
📊 Quality Score:
News: 14%
Publisher: 63%

Nederland Nieuws Nieuws

Nederland Laatste Nieuws,Nederland Headlines

The decision is a win for Moderna, which needs another revenue source amid plunging demand for its Covid vaccine, its only commercially available product.

The decision is a win for Moderna, which desperately needs another revenue source amid plunging demand for its Covid jab, its only commercially available product.

A positive recommendation from the CDC would allow Moderna's vaccine to compete against GSK and Pfizer, which launched their respective shots in the U.S. last fall. Pfizer's vaccine has so far lagged behind GSK's, but both shots have so far recorded hundreds of millions in sales.The approval demonstrates the versatility of Moderna's messenger RNA platform beyond treating Covid.

Moderna has said it expects to return to sales growth in 2025 and to break even by 2026, with the launch of new products.

Wij hebben dit nieuws samengevat zodat u het snel kunt lezen. Bent u geïnteresseerd in het nieuws, dan kunt u hier de volledige tekst lezen. Lees verder:

Schrijf commentaar

Nederland Laatste Nieuws, Nederland Headlines

Similar News:Je kunt ook nieuwsberichten lezen die vergelijkbaar zijn met deze die we uit andere nieuwsbronnen hebben verzameld.

FDA approves Moderna's RSV vaccine for seniors, the company's second-ever productThe decision is a win for Moderna, which needs another revenue source amid plunging demand for its Covid vaccine, its only commercially available product.
Bron: CNBC - 🏆 12. / 72 Lees verder »